Vitreoretinal Technologies begins enrollment for phase 3 trial of investigational diabetic retinopathy drug
Click Here to Manage Email Alerts
IRVINE, Calif. Vitreoretinal Technologies has begun enrollment in the United States and India for a phase 3 clinical trial evaluating the safety and efficacy of Vitreosolve, an investigational drug for treating patients with diabetic retinopathy, the company announced in a press release.
The study is the first of two pivotal trials required by the U.S. Food and Drug Administration for the submission of a new drug application, according to the press release.
Vitreoretinal Technologies is also developing Neurosolve, a neuronal rescue agent for treating patients with glaucoma and retinitis pigmentosa. Both Vitreosolve (carbamide) and Neurosolve are small molecules that have shown safety and efficacy for systemic use in phase 2 clinical trials, the release said.